SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. – ACAD

NEW YORK, NY / ACCESSWIRE / April 14, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On April 9, 2018, CNN reported that Nuplazid, Acadia’s Parkinson’s disease psychosis treatment, has been associated with more than 700 deaths, and that adverse event reports concerning the drug link it to additional life-threatening incidents, falls, insomnia, nausea, and fatigue.

On this news, Acadia’s share price fell $5.03, or 23.36%, to close at $16.50 on April 9, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 496103